Novo's CagriSema Shows 25% Weight Loss in Women
The company reports that its experimental injection improves upon the weight loss achieved by its blockbuster GLP-1 drug.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 3 articles since 20 Oct 2026. CNBC published first, on 20 October at 12:50 UTC; Quartz followed 40 min later. The most recent article, from Quartz, appeared on 20 October at 13:30 UTC.
Outlets reporting it: CNBC (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- CNBCNovo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
- QuartzNovo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
- QuartzNovo Nordisk sagte, dass CagriSema in einer neuen Analyse mit einem 25%igen Gewichtsverlust bei Frauen in Verbindung gebracht wurde.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis CNBC ·
- Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis Quartz
- Novo Nordisk sagte, dass CagriSema in einer neuen Analyse mit einem 25%igen Gewichtsverlust bei Frauen in Verbindung gebracht wurde. Quartz
In this story
- Novo
- CagriSema
- Wegovy